GPC3 and neoplasm: In summary, the combination of AAV-CC19 and GPC3-targeted CAR-T cell therapy designed in this study effectively increased the migration and infiltration of CAR-T cells into tumor tissues and increased the therapeutic effect of CAR-T cells.